^
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A1 - Approval
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive: A1 - Approval
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
CRLF2 rearrangement + JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
EPOR rearrangement
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
PDGFRB fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide + vincristine + methotrexate + pegaspargase
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
vincristine + mitoxantrone + dexamethasone + pegaspargase
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
bosutinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
vincristine liposomal
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
FLAG-IDA
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
clofarabine
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
cytarabine + methotrexate + idarubicin hydrochloride
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
cytarabine + etoposide IV + mitoxantrone
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
prednisone + vincristine + daunorubicin + pegaspargase
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
daratumumab
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
PBCAR0191
Sensitive: B - Late Trials
CD19 positive
B Acute Lymphoblastic Leukemia
CTX110
Sensitive: B - Late Trials
No biomarker
B Acute Lymphoblastic Leukemia
AUTO1
Sensitive: B - Late Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
venetoclax
Sensitive: C1 - Off-label
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: C1 - Off-label
KRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant: C3 – Early Trials
NRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant: C3 – Early Trials
TCF3-PBX1 fusion
B Acute Lymphoblastic Leukemia
idelalisib
Sensitive: C3 – Early Trials
PAK4 deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
CDKN2A deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
CD19 positive
B Acute Lymphoblastic Leukemia
CAR-T immunotherapy
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
rituximab + bortezomib
Sensitive: C3 – Early Trials
CD19 positive
B Acute Lymphoblastic Leukemia
YT-19
Sensitive: C3 – Early Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
MLL rearrangement
B Acute Lymphoblastic Leukemia
blinatumomab
Resistant: C3 – Early Trials
BCR-ABL1 Q252H + BCR-ABL1 V299L
B Acute Lymphoblastic Leukemia
venetoclax + ponatinib
Sensitive: C3 – Early Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
BCR-ABL1 E255V
B Acute Lymphoblastic Leukemia
venetoclax + ponatinib
Sensitive: C3 – Early Trials
CD20 expression
B Acute Lymphoblastic Leukemia
rituximab
Sensitive: C3 – Early Trials
HER-2 expression
Childhood B Acute Lymphoblastic Leukemia
trastuzumab
Resistant: C3 – Early Trials
TP53 mutation + IKZF3 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
TP53 mutation + IKZF1 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
IKZF3 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
TP53 deletion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
CD20 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
IKZF1 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
PD-1 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
PAX5 fusion
Childhood B Acute Lymphoblastic Leukemia
nintedanib
Sensitive: C3 – Early Trials
CD19 deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
MLL translocation
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
MLL-AFF1 fusion
B Acute Lymphoblastic Leukemia
venetoclax
Sensitive: C3 – Early Trials
ABCB1 3435C>T
B Acute Lymphoblastic Leukemia
imatinib
Sensitive: C3 – Early Trials
CD19 positive + CD20 positive
B Acute Lymphoblastic Leukemia
CD19-targeted CAR-T immunotherapy
Sensitive: C3 – Early Trials
CD20 positive
B Acute Lymphoblastic Leukemia
ofatumumab
Sensitive: C3 – Early Trials
CD19 positive
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib + blinatumomab
Sensitive: C3 – Early Trials
CD19 positive
B Acute Lymphoblastic Leukemia
PBCAR0191
Sensitive: C3 – Early Trials
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
VPD
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
CAR-T immunotherapy
Sensitive: C3 – Early Trials
TNFRSF13C expression
B Acute Lymphoblastic Leukemia
blinatumomab
Resistant: C3 – Early Trials
CD19 positive
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials